Crescita Therapeutics Inc.
CTX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 28.64% | 6.30% | 23.55% | 16.96% | -1.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 28.64% | 6.30% | 23.55% | 16.96% | -1.99% |
| Cost of Revenue | 13.05% | -5.14% | 43.92% | 33.65% | 22.38% |
| Gross Profit | 47.64% | 19.71% | 7.26% | 3.10% | -21.13% |
| SG&A Expenses | 14.06% | -1.76% | -5.73% | -1.36% | -0.28% |
| Depreciation & Amortization | 6.95% | -27.58% | -53.13% | -60.11% | -65.06% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.91% | -4.51% | 9.27% | 7.13% | 3.08% |
| Operating Income | 67.26% | 69.89% | 72.07% | 43.36% | -40.08% |
| Income Before Tax | 90.32% | 98.55% | 118.67% | 53.55% | -44.96% |
| Income Tax Expenses | 165.00% | 165.00% | -106.91% | -106.91% | -104.67% |
| Earnings from Continuing Operations | 89.98% | 98.22% | 117.82% | 57.05% | -26.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.98% | 98.22% | 117.82% | 57.05% | -26.55% |
| EBIT | 67.26% | 69.89% | 72.07% | 43.36% | -40.08% |
| EBITDA | 109.91% | 118.03% | 124.48% | 66.98% | -117.79% |
| EPS Basic | 88.90% | 98.08% | 118.67% | 55.73% | -32.41% |
| Normalized Basic EPS | 120.19% | 132.01% | 126.85% | 47.90% | -58.76% |
| EPS Diluted | 87.77% | 96.62% | 115.85% | 54.86% | -32.99% |
| Normalized Diluted EPS | 120.05% | 131.86% | 126.68% | 47.74% | -58.76% |
| Average Basic Shares Outstanding | -2.43% | -2.61% | -3.03% | -3.82% | -4.25% |
| Average Diluted Shares Outstanding | -2.28% | -2.46% | -2.88% | -3.69% | -4.25% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |